Cellectis Aktie

1,20 EUR -0,04 EUR -3,23 %

29.05.2025

FSE

1,43 USD +0,02 USD +1,42 %

29.05.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Div. Rendite0,00%

WKNA14QZE

ISINUS15117K1034

SymbolCLLS

Cellectis Aktien News

Sortieren:Datum Meistgelesen

21.05.25GlobeNewswireCellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025

12.05.25GlobeNewswireCellectis Reports Financial Results for the First Quarter 2025

07.05.25GlobeNewswireMonthly information on share capital and company voting rights

WerbungCellectis-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

06.05.25GlobeNewswireCellectis to Report First Quarter Financial Results on May 12, 2025

28.04.25GlobeNewswireCellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting

07.04.25GlobeNewswireMonthly information on share capital and company voting rights

13.03.25GlobeNewswireCellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

07.03.25GlobeNewswireCellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

06.03.25GlobeNewswireMonthly information on share capital and company voting rights

24.02.25GlobeNewswireCellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

04.02.25GlobeNewswireMonthly information on share capital and company voting rights

08.01.25GlobeNewswireMonthly information on share capital and company voting rights

07.01.25ZacksDo Options Traders Know Something About Cellectis (CLLS) Stock We Don't?

10.12.24GlobeNewswireCellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

04.12.24GlobeNewswireMonthly information on share capital and company voting rights

06.11.24GlobeNewswireMonthly information on share capital and company voting rights

05.11.24GlobeNewswireCellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

04.11.24GlobeNewswireCellectis Provides Business Updates and Financial Results for Third Quarter 2024

30.10.24GlobeNewswireCellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

22.10.24GlobeNewswireCellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

02.10.24GlobeNewswireMonthly information on share capital and company voting rights

04.09.24GlobeNewswireMonthly information on share capital and company voting rights

03.09.24GlobeNewswireCellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

26.08.24GlobeNewswireCellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

07.08.24GlobeNewswireCellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

06.08.24GlobeNewswireCellectis Provides Financial Results for the Second Quarter 2024

05.08.24GlobeNewswireMonthly information on share capital and company voting rights

01.08.24GlobeNewswireFDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment

25.07.24GlobeNewswireFDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

10.07.24ZacksDown -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)

05.07.24GlobeNewswireMonthly information on share capital and company voting rights

28.06.24GlobeNewswireCellectis Reports Results from Shareholders Meeting Held on June 28, 2024

20.06.24GlobeNewswireCellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

18.06.24ZacksCellectis (CLLS) Upgraded to Buy: Here's Why

18.06.24ZacksAfter Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)

12.06.24GlobeNewswireCellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

05.06.24GlobeNewswireMonthly information on share capital and company voting rights

04.06.24GlobeNewswireCellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

29.05.24GlobeNewswireCellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

28.05.24GlobeNewswireCellectis Reports Financial Results for First Quarter 2024

Cellectis News

Cellectis News: auf dieser Seite finden Sie alle Cellectis News und Nachrichten zur Cellectis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Cellectis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Cellectis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.